Literature DB >> 34191173

Methodological framework for radiomics applications in Hodgkin's lymphoma.

Martina Sollini1,2, Margarita Kirienko3, Lara Cavinato2,4, Francesca Ricci2, Matteo Biroli1, Francesca Ieva4,5, Letizia Calderoni6, Elena Tabacchi6, Cristina Nanni6, Pier Luigi Zinzani7, Stefano Fanti6, Anna Guidetti8,9, Alessandra Alessi8, Paolo Corradini8,9, Ettore Seregni8, Carmelo Carlo-Stella1,2, Arturo Chiti1,2.   

Abstract

BACKGROUND: According to published data, radiomics features differ between lesions of refractory/relapsing HL patients from those of long-term responders. However, several methodological aspects have not been elucidated yet.
PURPOSE: The study aimed at setting up a methodological framework in radiomics applications in Hodgkin's lymphoma (HL), especially at (a) developing a novel feature selection approach, (b) evaluating radiomic intra-patient lesions' similarity, and (c) classifying relapsing refractory (R/R) vs non-(R/R) patients.
METHODS: We retrospectively included 85 patients (male:female = 52:33; median age 35 years, range 19-74). LIFEx (www.lifexsoft.org) was used for [18F]FDG-PET/CT segmentation and feature extraction. Features were a-priori selected if they were highly correlated or uncorrelated to the volume. Principal component analysis-transformed features were used to build the fingerprints that were tested to assess lesions' similarity, using the silhouette. For intra-patient similarity analysis, we used patients having multiple lesions only. To classify patients as non-R/R and R/R, the fingerprint considering one single lesion (fingerprint_One) and all lesions (fingerprint_All) was tested using Random Undersampling Boosting of Tree Ensemble (RUBTE).
RESULTS: HL fingerprints included up to 15 features. Intra-patient lesion similarity analysis resulted in mean/median silhouette values below 0.5 (low similarity especially in the non-R/R group). In the test set, the fingerprint_One classification accuracy was 62% (78% sensitivity and 53% specificity); the classification by RUBTE using fingerprint_All resulted in 82% accuracy (70% sensitivity and 88% specificity).
CONCLUSIONS: Lesion similarity analysis was developed, and it allowed to demonstrate that HL lesions were not homogeneous within patients in terms of radiomics signature. Therefore, a random target lesion selection should not be adopted for radiomics applications. Moreover, the classifier to predict R/R vs non-R/R performed the best when all the lesions were used.

Entities:  

Keywords:  Feature selection; Lymphoma; Outcome prediction; PET/CT; Radiomics; Response prediction; Silhouette; Similarity

Year:  2020        PMID: 34191173     DOI: 10.1186/s41824-020-00078-8

Source DB:  PubMed          Journal:  Eur J Hybrid Imaging        ISSN: 2510-3636


  18 in total

1.  Prediction of disease-free survival by the PET/CT radiomic signature in non-small cell lung cancer patients undergoing surgery.

Authors:  Margarita Kirienko; Luca Cozzi; Lidija Antunovic; Lisa Lozza; Antonella Fogliata; Emanuele Voulaz; Alexia Rossi; Arturo Chiti; Martina Sollini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-09-24       Impact factor: 9.236

2.  PET positivity - the agony of choice: response assessment and interpretation of increased FDG uptake of residual mediastinal tissue after frontline therapy in Hodgkin lymphoma.

Authors:  Sarah Gillessen; Carsten Kobe; Andreas Engert; Bastian von Tresckow
Journal:  Leuk Lymphoma       Date:  2020-01-16

Review 3.  FDG-PET/CT in the management of lymphomas: current status and future directions.

Authors:  T C El-Galaly; D Villa; L C Gormsen; J Baech; A Lo; C Y Cheah
Journal:  J Intern Med       Date:  2018-07-24       Impact factor: 8.989

4.  Evaluation of PET texture features with heterogeneous phantoms: complementarity and effect of motion and segmentation method.

Authors:  M Carles; I Torres-Espallardo; A Alberich-Bayarri; C Olivas; P Bello; U Nestle; L Martí-Bonmatí
Journal:  Phys Med Biol       Date:  2016-12-29       Impact factor: 3.609

5.  18F-FDG PET uptake characterization through texture analysis: investigating the complementary nature of heterogeneity and functional tumor volume in a multi-cancer site patient cohort.

Authors:  Mathieu Hatt; Mohamed Majdoub; Martin Vallières; Florent Tixier; Catherine Cheze Le Rest; David Groheux; Elif Hindié; Antoine Martineau; Olivier Pradier; Roland Hustinx; Remy Perdrisot; Remy Guillevin; Issam El Naqa; Dimitris Visvikis
Journal:  J Nucl Med       Date:  2014-12-11       Impact factor: 10.057

6.  Association between textural and morphological tumor indices on baseline PET-CT and early metabolic response on interim PET-CT in bulky malignant lymphomas.

Authors:  Fayçal Ben Bouallègue; Yassine Al Tabaa; Marilyne Kafrouni; Guillaume Cartron; Fabien Vauchot; Denis Mariano-Goulart
Journal:  Med Phys       Date:  2017-08-02       Impact factor: 4.071

Review 7.  Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management.

Authors:  Stephen M Ansell
Journal:  Am J Hematol       Date:  2018-05       Impact factor: 10.047

8.  Recent Advances in the Pathobiology of Hodgkin's Lymphoma: Potential Impact on Diagnostic, Predictive, and Therapeutic Strategies.

Authors:  Diponkar Banerjee
Journal:  Adv Hematol       Date:  2011-01-18

9.  Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies.

Authors:  Theodoros Karantanos; Ioannis Politikos; Vassiliki A Boussiotis
Journal:  Blood Lymphat Cancer       Date:  2017-05-09

10.  CT-based texture analysis potentially provides prognostic information complementary to interim fdg-pet for patients with hodgkin's and aggressive non-hodgkin's lymphomas.

Authors:  B Ganeshan; K A Miles; S Babikir; R Shortman; A Afaq; K M Ardeshna; A M Groves; I Kayani
Journal:  Eur Radiol       Date:  2016-07-05       Impact factor: 5.315

View more
  1 in total

1.  FDG PET/CT to Predict Recurrence of Early Breast Invasive Ductal Carcinoma.

Authors:  Joon-Hyung Jo; Hyun Woo Chung; Young So; Young Bum Yoo; Kyoung Sik Park; Sang Eun Nam; Eun Jeong Lee; Woo Chul Noh
Journal:  Diagnostics (Basel)       Date:  2022-03-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.